These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18976073)

  • 1. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
    Khatri RG; Navaratne K; Weil RJ
    J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.
    Zawlik I; Kita D; Vaccarella S; Mittelbronn M; Franceschi S; Ohgaki H
    Brain Pathol; 2009 Apr; 19(2):188-94. PubMed ID: 18462472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
    Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
    J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
    El Hallani S; Marie Y; Idbaih A; Rodero M; Boisselier B; Laigle-Donadey F; Ducray F; Delattre JY; Sanson M
    J Neurooncol; 2007 Dec; 85(3):241-4. PubMed ID: 17568997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
    Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
    Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
    Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
    Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
    Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
    Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.